Jan 31: Hyderabad-based bio-pharma major Suven Life Sciences Ltd on Wednesday announced that it has been granted one product patent from Aripo (AP4415) and another one product patent from South Korea (10-18087922) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2033 and 2034 respectively.
According to the company, the granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Narcolepsy, Parkinson and Schizophrenia respectively.
Commenting on the development, Venkat Jasti, CEO of Suven, said, “we are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”
Suven shares surged more than 4% on BSE intraday today after the news came in. At 12.13 pm, the Re 1 face value shares were trading at Rs 225.50, up 0.49% from the previous closing of Rs 224.40.